. 2018 Mar; 9(13):10828-10829.
doi: 10.18632/oncotarget.24394.

The Yin and Yang of regulatory T cells in immunotherapy

Yan Li 1 James P Di Santo 1 
  • PMID: 29541377
  •     7 References

No abstract available

Keywords: IL-2 induced toxicity; cancer immunotherapy; humanized mice; regulatory T cells.

Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms.
Jamie B Spangler, Jakub Tomala, +7 authors, K Christopher Garcia.
Immunity, 2015 May 21; 42(5). PMID: 25992858    Free PMC article.
Highly Cited.
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.
Geok Choo Sim, Natalia Martin-Orozco, +9 authors, Laszlo Radvanyi.
J Clin Invest, 2013 Dec 03; 124(1). PMID: 24292706    Free PMC article.
Highly Cited.
Regulatory T cells control toxicity in a humanized model of IL-2 therapy.
Yan Li, Helene Strick-Marchand, +8 authors, James P Di Santo.
Nat Commun, 2017 Nov 28; 8(1). PMID: 29176694    Free PMC article.
IL-2: the first effective immunotherapy for human cancer.
Steven A Rosenberg.
J Immunol, 2014 Jun 08; 192(12). PMID: 24907378    Free PMC article.
Highly Cited. Review.
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.
Aron M Levin, Darren L Bates, +11 authors, K Christopher Garcia.
Nature, 2012 Mar 27; 484(7395). PMID: 22446627    Free PMC article.
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Regulatory T cells in cancer immunotherapy.
Atsushi Tanaka, Shimon Sakaguchi.
Cell Res, 2016 Dec 21; 27(1). PMID: 27995907    Free PMC article.
Highly Cited. Review.